ArticleNature communications2026
Biomarker-integrated prognostic stagings for Alzheimer's Disease.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort.Journal of Alzheimer's disease : JAD · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Accurately predicting disease progression remains a major challenge in Alzheimer's disease (AD). Here we show that a biomarker-integrated prognostic staging system can stratify progression risk across the disease course by jointly incorporating cognitive status, established risk factors, plasma biomarkers, and neuroimaging measures. In the K-ROAD cohort (N = 1,263), the dominant prognostic contributors varied by clinical context-GFAP in cognitively unimpaired individuals, hippocampal volume in mild cognitive impairment, and age in dementia-while plasma phosphorylated tau-217 provided consistent secondary prognostic information across stages. Outcome-specific staging captured clinically meaningful gradients of progression risk and informed construction of a unified six-stage framework (Stage 0-IVB) with distinct inflection points of accelerated decline. External validation in the ADNI cohort (N = 290) demonstrated consistent patterns of worsening prognosis, particularly in early and intermediate stages. This system provides a clinically interpretable approach to risk stratification and may serve as an exploratory framework for biomarker-integrated prognostic stratification in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.